Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | AXL | P30530 | 2/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2493390 | 0.86 | MAPT (0.47) | MAPTCASP1MRGPRX4KDM4EGRIN1 | |
| SCHEMBL12427702 | 0.84 | CFTR (0.48) | CFTRMAPTAXLMAP4K4CASP1 | |
| SCHEMBL11379519 | 0.83 | AXL (0.60) | AXLCASP1GAAIKBKETBK1 | |
| SCHEMBL9900680 | 0.83 | MAPK1 (0.52) | CFTRMAPTGAALMNAKDM4E | |
| SCHEMBL8623985 | 0.82 | AXL (0.59) | MAPTAXLGAALMNAKDM4E | |
| SCHEMBL17494845 | 0.82 | KDM4E (0.44) | CFTRMAPTMAP4K4MRGPRX4LMNA | |
| SCHEMBL14252346 | 0.79 | CFTR (0.60) | CFTRMAPTKDM4E | |
| SCHEMBL4910427 | 0.78 | PDGFRB (0.49) | MAPTCASP1GAALMNAKDM4E | |
| SCHEMBL16635454 | 0.78 | CFTR (0.47) | CFTRMAPTCASP1GAAMRGPRX4 | |
| SCHEMBL2490439 | 0.78 | PDGFRB (0.53) | CFTRMAPTMAP4K4MRGPRX4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066636-B1 | 5-PHENYL-NICOTINAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-10-26 | — | — | EP | disclosed |
| US-7781593-B2 | CB1 cannabinoid receptor antagonists/inverse agonists; 5-(4-chloro-phenyl)-N-((1R,2R)-2-hydroxy-cyclohexyl)-6-(3-methoxy-propyl)-nicotinamide for example; eating disorders, obesity, diabetes type II or non insulin dependent diabetes (NIDD), neuroinflammation, diarrhea, drug abuse | HOFFMANN-LA ROCHE INC. (US) | 2010-08-24 | — | — | US | disclosed |
| CN-101516849-A | 5-phenyl-nicotinamide derivatives | HOFFMANN LA ROCHE (CH) | 2009-08-26 | — | — | CN | disclosed |
| EP-2066636-A1 | 5-PHENYL-NICOTINAMIDE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| US-20080070931-A1 | CB1 cannabinoid receptor antagonists/inverse agonists; 5-(4-chloro-phenyl)-N-((1R,2R)-2-hydroxy-cyclohexyl)-6-(3-methoxy-propyl)-nicotinamide for example; eating disorders, obesity, diabetes type II or non insulin dependent diabetes (NIDD), neuroinflammation, diarrhea, drug abuse | HOFFMANN-LA ROCHE INC. | 2008-03-20 | — | — | US | disclosed |
| WO-2008031734-A1 | 5-PHENYL-NICOTINAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070931-A1 | CB1 cannabinoid receptor antagonists/inverse agonists; 5-(4-chloro-phenyl)-N-((1R,2R)-2-hydroxy-cyclohexyl)-6-(3-methoxy-propyl)-nicotinamide for example; eating disorders, obesity, diabetes type II or non insulin dependent diabetes (NIDD), neuroinflammation, diarrhea, drug abuse | CNR2, CNR1, GPR119 | CFTR 516/4885MAPT 3075/4885AXL 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.